Cas No.: | 483367-10-8 |
Chemical Name: | 9H-Purin-6-amine,9-cyclohexyl-N-[4-(4-morpholinyl)phenyl]-2-(1-naphthalenyloxy)- |
SMILES: | C1CCC(CC1)N2C=NC3=C2N=C(N=C3NC4=CC=C(C=C4)N5CCOCC5)OC6=CC=CC7=CC=CC=C76 |
Formula: | C31H32N6O2 |
M.Wt: | 520.62 |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Purmorphamine is a smoothened receptor agonist with an EC50 of 1 μM. |
In Vitro: | Purmorphamine (10, 20 μM) in combination with sirolimus significantly decreases cell numbers according to the MTT assay. Purmorphamine induces up-regulation of alkaline phosphatase activity and expression of RUNX-2 at day 14. Up-regulation of osteocalcin is detected at the 3 and 5 μM doses of purmorphamine on day 14 post-induction. Matrix mineralization remains unchanged in the presence or absence of purmorphamine[1]. Purmorphamine induces STAT3 phosphorylation in mouse ES cell line ES14 and mesenchymal stem cell line C3H10T1/2[2]. Purmorphamine up-regulates the expressionof markers of the osteoblast phenotype-ALP activity and bone-like nodule formationd-in human bonemarrow mesenchymal cells[3]. |